Multicenter Phase II Trial-Hematopoietic Stem Cell Transplantation for Treatment of Patients With FA Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
the incidence and quality of engraftment and hematopoietic reconstitution, the incidence of early transplant related mortality, the incidence and severity of acute GvHD and chronic GVHD.
David A Williams, MD
Children's Hospital Boston
United States: Food and Drug Administration
|Dana-Farber Cancer Institute||Boston, Massachusetts 02115|